CE IVD

Mouse anti-HER2

Cat. No.: AIB-30115 (1 ml Concentrate); AIB-30116 (0.5 ml Concentrate); AIB-30114 (6 ml Ready-to-use)

Instructions for use

Intended use

This antibody is designed for the specific localisation of the Her2/neu gene product in formalin-fixed, paraffinembedded tissue sections. Anti-Her2 antibody is intended for in vitro diagnostic use.

Specifications

Specificity:	HER2/neu (c-erbB2)
Immunogen:	Synthetic peptide corresponding to the intracellular domain of human HER2/neu protein
Clone:	CB11
Isotype:	Mouse IgG1
Species reactivity:	Human +, others not tested

Summary and Description

The gene product HER-2/neu is a 185 kDa transmembrane glycoprotein with tyrosine kinase activity and belongs to the protein family of epidermal growth factor receptors. The antibody clone CB11 is directed against the internal domain of the oncoprotein.

Approximately 20-30% of all breast cancer patients are showing overexpression of HER2 gene in their tumour cells. Additionally, some adenocarcinomas as well as carcinomas of the gastrointestinal tract and ovarian carcinomas are showing an overexpression of HER2. It was shown that overexpression of Her2 is correlated with bad prognosis. Since the HER2 protein was identified as major diagnostic target the immunohistochemical determination of HER2 has gained great importance. It was reported by different research groups that 15-30% of all invasive ductal breast carcinomas as well as 90% of ductal breast carcinomas in situ (DCIS) stain positive for HER2.

Reagent provided

Mouse monoclonal antibody from tissue culture supernatant in PBS with carrier protein and preservative for stabilisation in the following formats:

Concentrate:	1 ml	(Cat. No. AIB-30115)
Concentrate:	0.5 ml	(Cat. No. AIB-30116)
Ready-to-use:	6 ml	(Cat. No. AIB-30114)

Dilution of primary antibody

Dilution of Nordic Biosite' concentrated antibody depends on the detection system used. The final working dilution must always be determined by the user. The elaboration of staining protocol should be done by an experienced specialist. For Nordic Biosite' recommendations see chapter 'Staining procedure'.

Explanations of the symbols on the product label:

REF	Catalog Number Bestellnummer Reference du catalogue	LOT	Batch Code Chargenbezeichnung Code du lot	Manufacturer Nordic BioSite AB Propellervägen 4A S-183 62 Täby Sweden Tel: +46 (0)8 5444 33 40 Fax: +46 (0)8 756 94 90 info@nordicbiosite.com www.nordicbiosite.com
	Use By Verwendbar bis Utiliser jusque	IVD	In Vitro Diagnostic Medical Device In vitro Diagnostikum Dispositif médical de diagnostic in vitro	
	Consult Instructions for use Gebrauchsanweisung beachten Consulter les instructions d'utilisation		Temperature Limitation Lagerungstemperatur Limites de température	

Storage and handling
The antibody should be stored at 2-8°C without furt her dilution.
Dilutions of the concentrated antibody should be done with a suitable antibody dilution buffer (e.g. BCB-20005/BCB-20006 from Nordic Biosite). The diluted antibody should be stored at 2-8°C after use. Stability of this working solution depends on various parameters and has to be confirmed by appropriate controls.
The antibody provided is suitable for use until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Nordic Biosite' technical support or your local distributor.

Precautions
Use through qualified personnel only. Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water. Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur. Sodium azide (NaN3), used for stabilisation, is not considered hazardous material in the concentration used. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Sodium azide should be discarded in a large volume of running water to avoid formation of deposits. Material safety data sheets (MSDS) are available upon request.

Staining procedure
Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

Parameters	Nordic BioSites recommendations
*Pre-treatment	Heat Induced Epitope Retrieval (for example in Citrate Buffer pH 6.0 (BCB-20015/-20016)
*Control tissue	Breast carcinoma
*Working dilution	1:50-1:200 (for concentrated antibodies only)
*Incubation time	30-60 minutes

Quality control
The recommended positive control tissue for this antibody is breast carcinoma (20 – 30 % positive). We recommend carrying out a positive and a negative control with every staining run. Please refer to the instructions of the detection system for guidance on general quality control procedures.

Troubleshooting
If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

Expected results
This antibody stains positive in cell membranes of Her2 positive cells in formalin-fixed, paraffin-embedded tissue sections. Interpretation of the staining results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

Limitations of the Procedure
Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, alkaline phosphatase or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata et al, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.
Nordic Biosite warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Nordic Biosite be liable for any damages arising out of the use of the

Explanations of the symbols on the product label:

REF	Catalog Number Bestellnummer Reference du catalogue	LOT	Batch Code Chargenbezeichnung Code du lot	Manufacturer Nordic BioSite AB Propellervägen 4A S-183 62 Täby Sweden Tel: +46 (0)8 5444 33 40 Fax: +46 (0)8 756 94 90 info@nordicbiosite.com www.nordicbiosite.com
	Use By Verwendbar bis Utiliser jusque	IVD	In Vitro Diagnostic Medical Device In vitro Diagnostikum Dispositif médical de diagnostic in vitro	
	Consult Instructions for use Gebrauchsanweisung beachten Consulter les instructions d'utilisation		Temperature Limitation Lagerungstemperatur Limites de température	

reagent provided.

Performance characteristics

Nordic Biosite has conducted studies to evaluate the performance of the antibody for use with a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

Bibliography

Wright C et al. Cancer Res 49:2087-2090, 1989 Kruger S et al. Int J Cancer 102:514-518, 2002
Wright C et al. Britsh J Cancer 65:118-121, 1992 Lebeau A et al. J Clin Oncol 19:354-363, 2001
Slamon DJ et al. Science 237:177-182, 1987 Couturier J et al. Mod Pathol 13:1238-1243, 2000
Jacobs TW et al. Am J Clin Pathol 113:251-258, 2000 Pauletti G et al. J Clin Oncol 18:3651-3664, 2000
Gorlick R et al. J Clin Oncol 17:2781-2788, 1999 Seidmann AD et al. J Clin Oncol 19:2587-2595, 2001
Keshgegian AA et al. Am J Clin Pathol 108:456-463, 1997 O`Malley FP et al. Am J Clin Pathol 115:504-511, 2001
Garcia I et al. Ann Surg Oncol 10:234-241, 2003 Omata M et al. Am J Clin Pathol 73(5): 626-32, 1980
Nadji M and Morales AR Ann N.Y. Acad Sci 420:134-9, 1983

October 23, 2013 Rev: A1013 Doc: DBE_AIB-30115/-30115/-30116

Explanations of the symbols on the product label:

REF	Catalog Number Bestellnummer Reference du catalogue	LOT	Batch Code Chargenbezeichnung Code du lot	Manufacturer Nordic BioSite AB Propellervägen 4A S-183 62 Täby Sweden Tel: +46 (0)8 5444 33 40 Fax: +46 (0)8 756 94 90 info@nordicbiosite.com www.nordicbiosite.com
	Use By Verwendbar bis Utiliser jusque	IVD	In Vitro Diagnostic Medical Device In vitro Diagnostikum Dispositif médical de diagnostic in vitro	
	Consult Instructions for use Gebrauchsanweisung beachten Consulter les instructions d'utilisation		Temperature Limitation Lagerungstemperatur Limites de température	